Skip to main content

Atea Pharmaceuticals, Inc.

AVIR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001593899

No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Atea Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of AVIR: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders133119−14
Shares57.0M56.9M−193.8K (−0.3%)
Value$213.3M$170.6M−$42.7M (−20.0%)

New holders (6)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to AVIR in Q3 2023
InstitutionSharesValue% of portfolio
Pinebridge Investments, L.P.38,336$115.0K0.00%
SG Americas Securities, LLC34,497$103.0K0.00%
Verition Fund Management LLC22,954$68.9K0.00%
Pinnacle Wealth Planning Services, Inc.16,185$48.6K0.01%
HSBC Holdings PLC12,098$36.0K0.00%
GPS Wealth Strategies Group, LLC13$390.00%

Sold out (20)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.